CRSP - CRISPR: First Cut Has Deepest Value - Buy And Hold

• CRISPR is a pioneer in the gene editing space, licensing Nobel Prize winning technology to try to treat inherited diseases, cancers, and hematological conditions.
• The company's lead candidate is CTX001 being developed with Vertex - a potential blockbuster treatment for Sickle Cell Disease and Beta Thalassemia.
• If commercialized, CRISPR will receive $1.1bn from Vertex in milestone payments, but will earn only 40% of global net sales.
• The company's market cap is $8.9bn - high for a pre-revenue company whose assets other than CTX001 are years away from commercialization.
• There's no denying the technology is exciting. If CRISPR proves to be the "real deal", its valuation will soar, making the case for a buy and long-term hold strategy.

For further details see: